Project Grant R21CA309236
Award Date 7/15/26
Completion Date 6/30/28
Dollars Obligated $442K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Bronx, NY 10461, USA
Similar Awards
- Federal Grant Award Summary Albert Einstein College of Medicine received a $149,190 Project Grant award from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) dated December 18, 2025, with completion expected by September 19, 2027. The award supports biomedical training and research development focused on "Biomechanical Regulation of Chromatin States in Lung Cancer," investigating how mechanical forces in the lung tumor microenvironment...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Albert Einstein College of Medicine a $680,121 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective April 1, 2026, through March 31, 2031, to investigate immune evasion mechanisms in basal-like breast cancer (BLBC) precancer stem cells. The research focuses on understanding how precancer cancer stem cells (pre-CSCs) escape immunosurveillance through the SOX9-B7X signaling pathway, with the...
- Federal Grant Award Summary Albert Einstein College of Medicine received a $561,407 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) on June 18, 2026, with completion targeted for May 31, 2031. This award supports fundamental research investigating the causal mechanisms driving germline predisposition to myeloproliferative neoplasms (MPNs). The project utilizes genome-wide association study (GWAS) findings to elucidate how...
- Federal Project Grant Award Summary Albert Einstein College of Medicine received a $687,291 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective July 1, 2026 through June 30, 2031. The award funds fundamental research to elucidate molecular mechanisms by which cancer driver mutations suppress antitumor immune responses, specifically focusing on the role of MLL3 (KMT2C) mutations in promoting regulatory T cell (Treg)...
- Federal Grant Award Summary Albert Einstein College of Medicine received a $431,970 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) for the period April 1, 2026, through March 31, 2028. The award supports research to decipher resistance mechanisms to anti-TROP2 antibody-drug conjugates (ADCs), a newly approved class of cancer therapeutics exemplified by sacituzumab govitecan (SG) for treating triple-negative and hormone...
- Federal Project Grant Award Summary The National Cancer Institute awarded Albert Einstein College of Medicine a $431,970 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) effective July 1, 2026, through June 30, 2028. The award supports development and validation of TDAM (Tumor Microenvironment of Metastasis Doorway Activity-MRI), a non-invasive magnetic resonance imaging technique designed to detect and measure the activity of specialized intravasation...
- Federal Grant Award Summary Albert Einstein College of Medicine received a $692,197 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), awarded May 1, 2026, with completion targeted for April 30, 2031. The award supports development of methylthioadenosine phosphorylase (MTAP) transition state analog inhibitors designed to expand synthetic-lethal cancer therapeutic approaches. The research delivers highly specific, non-toxic MTAP...
- Federal Grant Award Summary Albert Einstein College of Medicine received a $695,154 Project Grant from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded July 1, 2026, with completion targeted for June 30, 2031. The grant funds research investigating inter-individual phenotypes of cancer gene mutation susceptibility in the human airway, with performance conducted in Bronx, New York. The project will employ single-molecule mutation...
- Federal Grant Award Summary Albany Medical College received a $648,579 Project Grant from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded June 1, 2026, with completion scheduled for May 31, 2031. The project, titled "Role of Tumor Biomechanics on Drug-Receptor Engagement," investigates how physical properties of the tumor microenvironment—including extracellular matrix stiffness, collagen density, and vascular...
- Federal Project Grant Award Summary Albert Einstein College of Medicine received a $885,632 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), awarded April 2, 2026, with completion targeted for March 31, 2028. The grant funds research to interrogate the relationship between erythroid differentiation and BCL-XL dependency in TP53-mutated acute myeloid leukemia (AML). The research addresses a critical clinical gap: TP53-mutated AML,...